Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function

OBJECTIVE: In November 2022, teplizumab-mzwv became the first drug approved to delay the onset of stage 3 type 1 diabetes in adults and children age ≥8 years with stage 2 type 1 diabetes on the basis of data from the pivotal study TN-10. RESEARCH DESIGN AND METHODS: To provide confirmatory evidence...

Descripción completa

Detalles Bibliográficos
Autores principales: Herold, Kevan C., Gitelman, Stephen E., Gottlieb, Peter A., Knecht, Laura A., Raymond, Ralph, Ramos, Eleanor L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545553/
https://www.ncbi.nlm.nih.gov/pubmed/37607392
http://dx.doi.org/10.2337/dc23-0675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545553/
https://www.ncbi.nlm.nih.gov/pubmed/37607392
http://dx.doi.org/10.2337/dc23-0675

Ejemplares similares